Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gavi

- PMLiVE

AZ’s COVID-19 vaccine demonstrates efficacy rate of up to 90%

Across two dosing regimens, vaccine has average efficacy of 70%

- PMLiVE

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Drug approved for emergency use in combination with Gilead's remdesivir

- PMLiVE

Pfizer, BioNTech to submit emergency use request for COVID-19 vaccine to FDA today

Shot could be available for high-risk populations in the US by middle of December

- PMLiVE

Healthineers’ COVID-19 antibody test launches in EU

Test can measure levels of neutralising antibodies in the blood

- PMLiVE

Chief investigator of Oxford Vaccine Group says data could be released before Christmas

AstraZeneca is developing a COVID-19 vaccine with Oxford University

- PMLiVE

AZ’s COVID-19 vaccine proves promising in elderly participants, new data shows

Immune responses were similar in younger and older adults

- PMLiVE

Pfizer, BioNTech’s COVID-19 vaccine is 95% effective, final analysis shows

Vaccine is over 94% effective in adults over 65 years of age

- PMLiVE

FDA set to publish reviews of data relating to COVID-19 vaccine EUAs

Agency set to publish data as part of 'transparency' efforts

- PMLiVE

Sinovac’s COVID-19 vaccine produces antibody response in mid-stage study

Level of antibodies in vaccinated group lower than recovered COVID-19 patients

- PMLiVE

EU secures 405 million doses of CureVac’s COVID-19 vaccine

CureVac revealed early stage data for its vaccine earlier this month

- PMLiVE

J&J advances COVID-19 vaccine into second phase 3 trial

ENSEMBLE study will enrol 60,000 people worldwide

- PMLiVE

Moderna’s COVID-19 vaccine is 94.5% effective, initial data suggests

The UK government has secured access to five million doses of the vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links